Common Cellular Protein Found to Help Wake Up Dormant HIV-1
Chemistry

Common Cellular Protein Found to Help Wake Up Dormant HIV-1

Researchers discover a metabolic and epigenetic pathway that controls viral latency, offering new clues for keeping the virus locked down.

By Bilal Abbasi
Published:
Email this Article
Common Cellular Protein Found to Help Wake Up Dormant HIV-1
Photo by National Institute of Allergy and Infectious Diseases on Unsplash

A common metabolic protein inside human cells plays a surprising role in helping human immunodeficiency virus type 1 (HIV-1) wake up from its dormant state, according to new research published in PLOS Pathogens. When scientists depleted this protein in laboratory models, viral replication and reactivation dropped significantly, pointing to a potential new avenue for keeping the virus locked down.

How Glucose and Metabolism Influence Viral Latency

While modern antiretroviral therapy successfully suppresses HIV-1 replication in patients, the virus establishes a stable, dormant reservoir inside long-lived memory T cells. This latent reservoir remains the primary barrier to a cure because stopping medication almost always triggers a rapid viral rebound. Efforts to purge this reservoir using latency-reversing agents have yielded inconsistent results, prompting researchers to explore block-and-lock strategies that reinforce viral silence without triggering widespread immune activation.

Previous studies noted that latently infected cells exhibit altered glucose handling and rely on antioxidant defenses to maintain their quiet state. Building on these clues, researchers led by a team of scientists investigated thioredoxin-interacting protein, a glucose-responsive host factor known to regulate cellular sugar uptake. Until now, the exact role of this protein in controlling viral transcription and latency remained unmapped.

Fig 1: Increased glucose availability is associated with HIV-1 latency reversal and TXNIP expression. (A-D) Latency reversal in J-Lat A2 (A), J-Lat 10.6 (B), U1 (C), and ACH2 (D) cells cultured with increasing glucose concentrations, as evidenced by enhanced GFP expression (J-Lat) measured by flow cytometry and increased p24 levels (U1, ACH2) measured by ELISA. (E) Immunoblot analysis in U1 cells showing that elevated glucose concentrations enhance latency reversal under suboptimal LRAs stimulation. For quantitative panels, data are presented as mean ± SD from three independent biological experiments (n = 3), with each biological replicate derived from an independently performed experiment. Technical replicates within each experiment are averaged before statistical analysis. Individual data points represent biological replicates. The immunoblot shown in panel E is representative of three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparison post hoc test was used to
Increased glucose availability is associated with HIV-1 latency reversal and TXNIP expression. (A-D) Latency reversal in J-Lat A2 (A), J-Lat 10.6 (B), U1 (C), and ACH2 (D) cells cultured with increasing glucose concentrations, as evidenced by enhanced GFP expression (J-Lat) measured by flow cytometry and increased p24 levels (U1, ACH2) measured by ELISA. (E) Immunoblot analysis in U1 cells showing that elevated glucose concentrations enhance latency reversal under suboptimal LRAs stimulation. For quantitative panels, data are presented as mean ± SD from three independent biological experiments (n = 3), with each biological replicate derived from an independently performed experiment. Technical replicates within each experiment are averaged before statistical analysis. Individual data points represent biological replicates. The immunoblot shown in panel E is representative of three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparison post hoc test was used to Credit: Ziyao Wu et al. / PLOS Pathogens

Experimental Findings in Cell Lines and Primary T Cells

The investigators tested the function of the protein across multiple experimental settings, including latently infected cell lines and primary cells isolated from healthy donors and individuals living with HIV-1 who were receiving suppressive therapy. When they silenced the gene encoding the protein using targeted ribonucleic acid interference, they observed an approximately 36 to 50 percent drop in viral particle release and lower transcriptional activity at the viral promoter region.

Conversely, artificially increasing the expression of the protein boosted viral transcription and enhanced the effectiveness of latency-reversing drugs. Chromatin immunoprecipitation assays further revealed that the protein associates with viral deoxyribonucleic acid sequences and interacts with cellular transcriptional machinery such as bromodomain-containing protein 4 and cyclin-dependent kinase 9, suggesting it acts as a cofactor in driving viral gene expression.

Uncovering an Epigenetic Regulatory Circuit

To understand what controls the protein, the team examined an epigenetic silencer known as enhancer of zeste homolog 2, which acts as the catalytic subunit of polycomb repressive complex 2. Elevated glucose levels decreased the abundance of this silencer, while pharmacological inhibition or genetic knockdown of the silencer increased the production of the metabolic protein and promoted viral reactivation.

Fig 2: TXNIP is functionally associated with HIV-1 replication. (A) Immunoblot analysis of TXNIP knockdown efficiency in TZM-bl cells using independent shRNAs. (B) HIV-1 LTR-driven luciferase activity (left panel) and cell viability (right panel) were measured in HIV-1IIIB-infected TZM-bl cells transduced with the indicated TXNIP-targeting shRNAs. (C) Immunoblot analysis of the expression levels of the TXNIP-Flag in TZM-bl cells. (D) Luciferase activity in TZM-bl cells ectopically expressing TXNIP shows increased luciferase signals relative to vector control. (E) Luciferase activity is restored in TXNIP-depleted TZM-bl cells transfected with TXNIP-Flag expression plasmid. (F) Immunoblot analysis of TXNIP knockdown efficiency in Jurkat T cells using independent shRNAs. (G) HIV-1 particle release in Jurkat T cells transduced with shTXNIP, measured by p24 ELISA at 72 hpi. (H-J) Extracellular p24 levels in culture supernatants from the corresponding in vitro HIV-1IIIB-infected primary hPBMCs from
TXNIP is functionally associated with HIV-1 replication. (A) Immunoblot analysis of TXNIP knockdown efficiency in TZM-bl cells using independent shRNAs. (B) HIV-1 LTR-driven luciferase activity (left panel) and cell viability (right panel) were measured in HIV-1IIIB-infected TZM-bl cells transduced with the indicated TXNIP-targeting shRNAs. (C) Immunoblot analysis of the expression levels of the TXNIP-Flag in TZM-bl cells. (D) Luciferase activity in TZM-bl cells ectopically expressing TXNIP shows increased luciferase signals relative to vector control. (E) Luciferase activity is restored in TXNIP-depleted TZM-bl cells transfected with TXNIP-Flag expression plasmid. (F) Immunoblot analysis of TXNIP knockdown efficiency in Jurkat T cells using independent shRNAs. (G) HIV-1 particle release in Jurkat T cells transduced with shTXNIP, measured by p24 ELISA at 72 hpi. (H-J) Extracellular p24 levels in culture supernatants from the corresponding in vitro HIV-1IIIB-infected primary hPBMCs from Credit: Ziyao Wu et al. / PLOS Pathogens

Further analysis showed that this epigenetic control operates indirectly through a transcription factor designated as ETV1. The researchers found that the silencer normally represses the ETV1 gene by depositing repressive histone marks. When that repression is lifted, ETV1 binds directly to the promoter region of the metabolic protein, driving up its expression and facilitating viral transcription.

Testing a Small Molecule Probe for Viral Suppression

To evaluate whether this pathway can be targeted pharmacologically, the team tested a small-molecule compound known as SRI-37330, which binds to the metabolic protein. In infection assays across multiple viral strains and cell types, the compound suppressed viral replication with half-maximal inhibitory concentration values ranging from 0.23 to 2.80 micromolars. It also reduced virus reactivation when cells were stimulated with latency-reversing agents.

Fig 3: TXNIP is associated with HIV-1 LTR-containing chromatin and LTR-associated transcriptional regulation. (A-D) Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR) analyses of TXNIP-associated signals at HIV-1 LTR-containing chromatin. (A) TXNIP-associated ChIP-qPCR signal at the HIV-1 5’-LTR in HIV-1IIIB-infected TZM-bl cells. (B) Effect of TXNIP knockdown on the LTR-associated TXNIP ChIP-qPCR signal in TZM-bl cells. (C) TXNIP-associated ChIP-qPCR signal at the HIV-1 5’-LTR in HIV-1IIIB-infected Jurkat T cells. (D) Effect of TXNIP knockdown on the LTR-associated TXNIP ChIP-qPCR signal in HIV-1IIIB-infected Jurkat T cells. IgG was used as a negative immunoprecipitation control. (E) Quantification of nascent HIV-1 transcripts across four regions of the LTR (Initiation, Proximal (Prox), Intermediate (Int), and Distal (Dis)) in HIV-1IIIB-infected Jurkat T cells following TXNIP knockdown (shTXNIP treatment) by RT-qPCR with specific primers. (F) Nascent HIV-1 transcripts in TXNIP-overex
TXNIP is associated with HIV-1 LTR-containing chromatin and LTR-associated transcriptional regulation. (A-D) Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR) analyses of TXNIP-associated signals at HIV-1 LTR-containing chromatin. (A) TXNIP-associated ChIP-qPCR signal at the HIV-1 5’-LTR in HIV-1IIIB-infected TZM-bl cells. (B) Effect of TXNIP knockdown on the LTR-associated TXNIP ChIP-qPCR signal in TZM-bl cells. (C) TXNIP-associated ChIP-qPCR signal at the HIV-1 5’-LTR in HIV-1IIIB-infected Jurkat T cells. (D) Effect of TXNIP knockdown on the LTR-associated TXNIP ChIP-qPCR signal in HIV-1IIIB-infected Jurkat T cells. IgG was used as a negative immunoprecipitation control. (E) Quantification of nascent HIV-1 transcripts across four regions of the LTR (Initiation, Proximal (Prox), Intermediate (Int), and Distal (Dis)) in HIV-1IIIB-infected Jurkat T cells following TXNIP knockdown (shTXNIP treatment) by RT-qPCR with specific primers. (F) Nascent HIV-1 transcripts in TXNIP-overex Credit: Ziyao Wu et al. / PLOS Pathogens

Surface plasmon resonance and cellular thermal shift assays confirmed direct target engagement between the compound and the protein. Furthermore, the suppressive effect of the compound was attenuated in cells where the protein had been genetically depleted, indicating that the protein contributes to the pharmacological activity of the drug. Cytotoxicity assays showed favorable selectivity indices, and flow cytometry analysis of peripheral blood mononuclear cells indicated no obvious induction of immune activation markers.

Study Limitations and Next Steps

The authors note that the research was conducted primarily in laboratory models and ex vivo primary cells, which cannot fully capture the complexity of viral reservoirs in living humans. Additionally, the small-molecule compound used in the experiments was originally investigated in metabolic research settings, meaning its safety and pharmacological behavior in HIV-infected individuals require thorough clinical evaluation. Future studies involving humanized animal models and broader clinical cohorts will be necessary to determine whether targeting this metabolic and epigenetic axis can translate into effective therapies for maintaining durable viral remission.

The research was published in PLOS Pathogens on November 16, 2026.

Fact Checked

This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.

Last reviewed on .

Article history

  • Latest version

Reference(s)

  1. Wu, Ziyao., et al. “TXNIP contributes to HIV-1 transcriptional competence and inducible reactivation through an EZH2-ETV1 regulatory pathway.” PLOS Pathogens, vol. 22, no. 11, November 16, 2026, pp. e1014748 Public Library of Science (PLoS), doi: 10.1371/journal.ppat.1014748. <https://doi.org/10.1371/journal.ppat.1014748>.

Cite this page:

Abbasi, Bilal. “Common Cellular Protein Found to Help Wake Up Dormant HIV-1.” BioScience. BioScience ISSN 2521-5760, 17 November 2026. <https://www.bioscience.com.pk/en/subject/chemistry/txnip-contributes-to-hiv-1-transcriptional-competence-and-inducible-reactivation-through-an-ezh2-etv1-regulatory-pathway>. Abbasi, B. (2026, November 17). “Common Cellular Protein Found to Help Wake Up Dormant HIV-1.” BioScience. ISSN 2521-5760. Retrieved November 17, 2026 from https://www.bioscience.com.pk/en/subject/chemistry/txnip-contributes-to-hiv-1-transcriptional-competence-and-inducible-reactivation-through-an-ezh2-etv1-regulatory-pathway Abbasi, Bilal. “Common Cellular Protein Found to Help Wake Up Dormant HIV-1.” BioScience. ISSN 2521-5760. https://www.bioscience.com.pk/en/subject/chemistry/txnip-contributes-to-hiv-1-transcriptional-competence-and-inducible-reactivation-through-an-ezh2-etv1-regulatory-pathway (accessed November 17, 2026).
End of the article